10 Best FTSE Dividend Stocks To Buy Now

3. GSK plc (NYSE:GSK)

Dividend Yield as of January 3: 4.67%

Number of Hedge Fund Holders: 38

GSK plc (NYSE:GSK) is a global healthcare company that offers vaccines for shingles, meningitis, flu, and respiratory syncytial virus, as well as medicines for HIV, cancer, respiratory diseases, and antibiotics. GSK plc (NYSE:GSK), with a yield of 4.67% as of January 3, is one of the best FTSE dividend stocks to buy.

In November 2024, GSK plc (NYSE:GSK) partnered with Vesalius Therapeutics in a deal worth up to $650 million to develop Parkinson’s disease drugs. The company will pay $80 million upfront, with additional payments for full rights to the program, which uses AI and human avatars to identify treatments. This expands GSK’s pipeline into neurodegenerative diseases.

GSK plc (NYSE:GSK) had a strong third quarter with 9% sales growth and 19% profit growth year-to-date, driven by Specialty Medicines and pipeline progress, particularly in oncology and HIV. The company resolved most of the Zantac litigation, removing a major risk. Vaccine sales were down, but both Arexvy and Shingrix maintained strong market shares. GSK plc (NYSE:GSK)’s operating profit and EPS grew 5%, with a 19% increase in operating profit year-to-date. The company generated £5.3 billion in cash flow, supporting investments and a 7% dividend increase. GSK also made strong progress in its pipeline, with plans for five major product launches next year.

Insider Monkey’s third quarter database indicates that 38 hedge funds were bullish on GSK plc (NYSE:GSK), compared to 36 funds in the earlier quarter. Fisher Asset Management, Arrowstreet Capital, and Renaissance Technologies were major shareholders of the company.